South Korean biopharmaceutical company Celltrion has announced the cancellation of 9.11 million treasury shares, valued at approximately 1.72 trillion won ($1.1 billion), marking the largest share cancellation in its history.

Celltrion has announced a license-in agreement with Korean biopharma company KoBioLabs for three microbiome-based drug candidates aimed at treating intestinal diseases.

Celltrion wins 294.9 bln-won drug substance supply deal from global firm  Yonhap News Agency

Korean biopharmaceutical company Celltrion announced its entry into the global obesity drug market, developing both an oral pill and an injectable treatment for weight loss.

Celltrion has officially launched its autoimmune disease treatment, Omlyclo, in Brazil, marking a strategic move to expand its presence in the Latin American pharmaceutical market.

Celltrion announced a 1.23 trillion won ($820 million) investment to construct two new plants in Songdo, Incheon, aiming to boost its biosimilar production capacity by 180,000 liters to meet rising global demand.

Celltrion said Friday it will immediately apply newly eased US biosimilar development rules to its pipeline, a move expected to cut development costs and shorten timelines.

Celltrion's near-term outlook looks solid. The Korean biosimilar giant has just posted its strongest annual earnings on record, underscoring the resilience of its core portfolio. But beyond the upbeat numbers lies a more consequential test. Seo Jin-seok, the 42-year-old CEO and eldest son of founder and Chair Seo Jung-jin, must now prove he can drive Celltrion's next growth engine by advancing its new drug pipelines and expanding its global footprint. In January, Seo stepped onto the main stage

Celltrion announced it has received product approval from the Japanese Ministry of Health, Labor and Welfare for Omlyclo and Eydenzelt, two biosimilars for allergic and ophthalmic diseases, respectively.

Celltrion said Tuesday it has signed a 294.9 billion won ($198 million) contract manufacturing agreement with an undisclosed global pharmaceutical company to supply drug substance. The three-year deal runs from 2027 to 2029 and includes an option to expand to 375.4 billion won upon mutual agreement. The contract underscores Celltrion’s accelerating push into the global contract development and manufacturing organization market. Earlier this year, the company signed a 678.7 billion won CMO deal w

Celltrion reports significant prescription growth and leading market shares for its key biosimilar products across Asian markets, with its autoimmune treatment Remsima showing dominant presence.